The NIO $NIO Inc.(NIO)$ stock price fell by -1.46% on Tuesday, 22nd Aug 2023 from $10.95 to $10.79. During the last trading day the stock fluctuated 7.59% from a day low at $10.53 to a day high of $11.33. The price has fallen in 8 of the last 10 days and is down by -23.31% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -12 million shares and in total, 42 million shares were bought and sold for approximately $453.77 million.Given the current short-term trend, the stock is expected to rise 62.37% during the next 3 months and, with a 90% probability hold a price between $17.52 and $27.30 at the end of this 3-month period.NIO

The Marathon Patent $Marathon Digital Holdings Inc(MARA)$ stock price fell by -9.26% on Thursday, 17th Aug 2023 from $13.50 to $12.25. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 8.36% from a day low at $12.20 to a day high of $13.22. The price has fallen in 7 of the last 10 days and is down by -26.03% for this period. Volume has increased on the last day by 12 million shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 34 million shares were bought and sold for approximately $414.00 million.Given the current short-term trend, the stock is expected to rise 60.03% during the next 3 months and, with a 90% probability hold a

The Fortinet $Fortinet(FTNT)$ stock price gained 1.30% on Thursday, 10th Aug 2023, rising from $59.78 to $60.56. It has now gained 4 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 3.56% from a day low at $60.07 to a day high of $62.21. The price has risen in 8 of the last 10 days but is still down by -20.92% for this period. Volume fell on the last day by -2 million shares and in total, 11 million shares were bought and sold for approximately $665.16 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of

SummaryTango Therapeutics is advancing in cancer treatment with Phase 1/2 clinical trials for TNG908 and TNG462, targeting MTAP-deleted tumors.Tango's stock soared by over 100% following Mirati's announcement on their unique PRMT5 inhibitor, emphasizing potential in MTAP-deleted cancer treatment.Tango's financial position shows $310.7 million in assets, adequate until 2026, though a careful look at cash runway is needed.Investment recommendation for TNGX stock is a "Hold" due to optimism in clinical prospects, yet perspective is advised for early-stage trials and financial support needs.Klaus VedfeltIntroductionTango Therapeutics $Tango Therapeutics Inc.(TNGX)$ focuses on the discovery and development of next-generation precision medicines to